Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 13, 2025 06:03 ET | Source: Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

~ Achieved First Quarter 2025 Total Net Revenues of $8.8 Million, Up 18% Year Over Year ~ ~ Positive Momentum from Company’s Refined, Targeted Sales Strategy and Enhanced Patient Support Services ~...
May 07, 2025 17:10 ET | Source: Knight Therapeutics

Knight Therapeutics Inc. announces voting results from the Annual General Meeting

MONTREAL, May 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a pan-American (ex-US) specialty pharmaceutical company, announced today the voting...
May 06, 2025 08:01 ET | Source: Ardelyx, Inc.

Ardelyx Presents Data Supporting IBSRELA® (tenapanor) at Digestive Disease Week 2025 Conference

WALTHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
May 01, 2025 16:01 ET | Source: Ardelyx, Inc.

Ardelyx Reports First Quarter 2025 Financial Results and Provides Business Update

Company reports $74.1 million in Q1 total revenue, reflecting 61% growth year-over-year IBSRELA net product sales revenue of $44.4 million; XPHOZAH net product sales revenue of $23.4 million ...
April 29, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors

WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 27, 2025 15:00 ET | Source: Precede Biosciences, Inc.

Precede Biosciences Presents Data at AACR 2025 Demonstrating Ability to Resolve Gene Expression for Thousands of Tumor-Specific Genes from a Simple Blood Test

Comprehensive epigenomic platform enables systematic and quantitative prediction of tumor gene expression from cell-free DNAGenes include key targets for next generation precision medicines, such as...
April 24, 2025 08:01 ET | Source: Ardelyx, Inc.

Ardelyx Announces Three Abstracts Accepted for Poster Presentations at Digestive Disease Week 2025 Conference

WALTHAM, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 22, 2025 08:44 ET | Source: Sixty Degrees Pharmaceuticals

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

60 Degrees Pharma survey suggests babesiosis affects up to 3M Americans—vastly more than CDC data—and may underlie millions of chronic fatigue cases.
April 17, 2025 08:00 ET | Source: Ardelyx, Inc.

Ardelyx to Report First Quarter 2025 Financial Results on May 1, 2025

WALTHAM, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class...
April 16, 2025 08:00 ET | Source: Salarius Pharmaceuticals, Inc.

Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide...